Neo-adjuvant endocrine therapy in breast cancer
10.3760/cma.j.issn.1006-9801.2011.02.026
- VernacularTitle:乳腺癌新辅助内分泌治疗进展
- Author:
Qian LIU
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Postmenopause;
Aromatase inhibitor;
Neo-adjuvant endocrine therapy
- From:
Cancer Research and Clinic
2011;23(2):139-141
- CountryChina
- Language:Chinese
-
Abstract:
Nco-adjuvant endocrine therapy has provided opened new alternatives for locally advanced breast cancer, especially for patient groups such as the elderly, those who are not suited for chemotherapy, and those whose response may not be optimal. The latest generation of endocrine therapy for breast cancer,aromatase inhibitors, has proved superior to tamoxifen in terms of toxicity and efficacy in the adjuvant setting.Compared with neo-adjuvant chemotherapy, the appropriate patients to receive nco-adjuvant endocrine therapy can achieve similar short-term benefit. However, because of fewer long-term follow up results, the overall prognosis is not clear.
